Abstract 137P
Background
Recent single-cell DNA sequencing (scDNA-seq) technologies have enabled the parallel investigation of thousands of individual cells. This is required for accurately reconstructing tumour evolution, during which cancer cells acquire a multitude of different genetic alterations. Although the evolutionary analysis of scDNA-seq datasets is complex due to their unique combination of errors and missing data, several methods have been developed to infer single-cell tumour phylogenies by integrating estimates of the false positive and false negative error rates. This integration relies on the assumption that errors are uniformly distributed both within and across cells. However, this assumption does not always hold; error rates depend on sequencing coverage, which is not constant within or across cells in a sequencing experiment due to, e.g., copy-number alterations and the replication status of a cell, limiting the accuracy of existing methods.
Methods
To address this challenge, we developed PHANTOM, a novel single-cell phylogenetic method that integrates raw sequencing read counts into a statistical framework to robustly correct the errors and missing data. PHANTOM includes bootstrapping to correct for high error frequency genomic positions and a fast probabilistic heuristic based on hypothesis testing to distinguish the remaining errors from truly observed genotypes.
Results
We demonstrate the improved accuracy and robustness of our method compared to existing approaches across several simulation settings. To demonstrate its impact, we applied our method to scDNA-seq datasets comprising >25,000 cells from 31 patients with triple-negative breast cancer or high-grade serous ovarian cancer, as well as targeted scDNA-seq from a cohort of 123 patients with acute myeloid leukaemia, revealing more accurate phylogenies consistent with copy-number alterations.
Conclusions
We developed PHANTOM, a novel single-cell phylogenetic method that accurately and robustly infers single-cell tumour phylogenies. We applied PHANTOM to scDNA-seq cancer datasets, revealing its potential to investigate tumour evolution at unprecedented resolution.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Cancer Research UK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract